Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

• DOI: 10.2147/copd.s103105
• Publication Date: 2016-04-21T20:10:06Z
• Authors: Yoshinosuke Fukuchi; Koichiro Tatsumi; Hiromasa Inoue; Yukinori Sakata; Kai Shibata; Hideaki Miyagishi; Yasuhiro Marukawa; Masakazu Ichinose
• Keywords: Clinical endpoint; Vital capacity

Background/aim: Lysozyme (mucopeptide N -acetyl-muramyl hydrolase) is widely used as a mucolytic and anti-inflammatory agent in Japan. We evaluated the effects of long-term lysozyme administration on COPD exacerbation. Methods: In 1-year, randomized, double-blind, placebo-controlled, parallel trial, patients with moderate-to-severe one or more episodes exacerbation previous year before enrollment were selected. (270 mg) placebo was administered orally for 52 weeks an add-on to standard therapies such bronchodilators. exacerbation, pulmonary function, assessment test scores analyzed. An defined worsening than symptom (cough, sputum volume, purulent sputum, breathlessness) leading change medication. The primary endpoint rate. Results: A total 408 randomly assigned groups. baseline characteristics similar between two rate not significantly different groups (1.4 vs 1.2; P =0.292, Poisson regression). However, subgroup analysis showed that might reduce airway-dominant phenotype (1.2 1.6). Moreover, median time first longer group group. levels improvement forced expiratory volume 1 second statistically groups, but always greater over study. Conclusion: using therapy compared insufficient prevent Keywords: lysozyme, second,